The relapsed or refractory diffuse large B-cell lymphoma market comprises products developed to treat patients suffering from lymphoma whose disease relapsed or became refractory to initial treatment. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, rapidly growing cancer affecting B lymphocytes. The standard treatments for DLBCL include chemotherapy with regimens such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) and targeted therapy like Rituximab. However, 30-40% of patients experience relapse or refractory disease, having no standard treatment options. The emergence of new targeted therapies has expanded treatment options for these high-risk patients.
The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the relapsed or refractory diffuse large B-cell lymphoma are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These players are focusing on developing innovative targeted therapies for improving treatment outcomes.
Some of the key opportunities in the market include rising demand for CAR T-cell therapies, orphan drug designation, and high unmet needs. Several pharmaceutical companies are developing CAR T-cell therapies like axicabtagene ciloleucel and mogamulizumab.
Globally, the market is witnessing expansion in Asia Pacific region owing to rising healthcare expenditure, increasing awareness about relapsed DLBCL, and growth in healthcare infrastructure. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period.
Market drivers
The rising geriatric population is a major growth driver for this market. Age is an important risk factor for Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Size and majority diagnosed patients are above 60 years of age. According to WHO, the proportion of the world’s population over 60 years will nearly double from 12% to 22% between 2015 and 2050. The elderly patients are generally at higher risk of relapse post initial treatment and require effective therapies for relapsed DLBCL. Therefore, the growing geriatric demographic globally will augment the demand for advanced targeted drugs in this market.
PEST Analysis
Political: Government regulations related with the approval of drugs and medical facilities affects the market growth. Regulations related with pricing of drugs also impacts the profit margins of vendors.
Economic: Rise in per capita disposable income fuels the demand of advanced healthcare solutions. However, high treatment cost of targeted therapies restrains the market.
Social: Increasing awareness about diseases and availability of treatment propels the patients seeking advanced therapies. Growing geriatric population also drives the requirement for Relapsed or Refractory Diffuse Large B-cell Lymphoma therapeutics.
Technological: Advancements in targeted therapies such as antibody drug conjugates and chimeric antigen receptor T-cell therapies improves the treatment landscape. Continued research also helps in widening treatment options.
The United States represents the largest market for Relapsed or Refractory Diffuse Large B-cell Lymphoma, in terms of value. Availability of advanced healthcare infrastructure along with presence of leading players in the country drives the US market. Reimbursement programs also aid patients to avail quality treatments.
Asia Pacific exhibits the fastest growth for Relapsed or Refractory Diffuse Large B-cell Lymphoma market. Rise in healthcare spending along with growing incidences of cancer in developing countries of the region fuels the market. Furthermore, improving awareness about treatments and emerging economies expanding access to care boosts the APAC Relapsed or Refractory Diffuse Large B-cell Lymphoma market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
